Wilson's Disease Support Group - UK

Striving to promote the wellbeing of patients with Wilson's disease, their families and friends

Trientine Dihydrochloride: Change of Name to Cufence®

Statement by Univar, manufacturers of Cufence® (Nov 2020)

Trientine Dihydrochloride capsules 300 mg changes its name to Cufence® 200 mg hard capsules

Since 1985, trientine has been licensed in the UK. As of 2013, Univar Solutions B.V. has been the UK Marketing Authorisation Holder for Trientine Dihydrochloride 300 mg. The company has received a centralized European Marketing Authorization for this medicine in 2019 - with the brand name Cufence® 200 mg.1 From November 2020 onwards, Trientine Dihydrochloride 300 mg is available in the UK as Cufence®. Trientine Dihydrochloride 300 mg states the weight including the salt, whereas Cufence® 200 mg states only the weight of the active moiety trientine. Capsules of both products contain 300 mg trientine dihydrochloride equivalent to 200 mg trientine. 2, 3

Cufence® is a medicine used for the treatment of Wilson's disease in adults, adolescents and children aged 5 years or older. It is for use by patients who cannot take another medicine, D-Penicillamine, because of side effects.2 Trientine has been used for over 30 years to treat patients with Wilson's disease. The safety of the medicine has been shown to be similar to that of other trientine medicines.1

Cufence® does not require any special storage conditions unopened. After opening the bottle, store in a refrigerator (2ºC-8ºC).2

Adverse Events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard

Side effects can also be reported to Univar Solutions B.V., by emailing drugsafety@pharmalex.com

If you have any remaining questions, please consult your doctor.

1. European Medicines Agency: EMA/410631/2019 – Cufence EPAR Medicines Overview

https://www.ema.europa.eu/en/documents/overview/cufence-epar-medicine-overview_en.pdf, August 2020

2. Cufence 200 mg Summary of Product Characteristics (SmPC) (Cufence SmPC, 2020)

3. Trientine Dihydrochloride 300 mg Summary of Product Characteristics (SmPC) (Trientine Dihydrochloride 300 mg SmPC, 2019)